Pulmatrix to Present Data on PUR118 for Respiratory Diseases at European Respiratory Society Congress

Preclinical Data Highlight Potential of iCALM Dry Powder to Reduce Acute Exacerbations of the Lung Associated with COPD, Asthma and Respiratory Infections

LEXINGTON, Mass.--(BUSINESS WIRE)--Sep 22, 2011 - Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands. The oral and poster presentations at ERS 2011 will highlight the potential of PUR118 as an effective treatment for acute exacerbations of the lung associated with chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), and serious respiratory infections. PUR118, the lead clinical candidate using Pulmatrix's proprietary iCALM technology, is currently in Phase 1b human clinical trials for COPD.

The schedule and details of the presentations relating to PUR118 at ERS 2011 are as follows:

Abs. ID/Title:     P2552 - Inhaled calcium based dry powder inhibits rhinovirus-induced inflammation and exacerbation in a mouse model of allergic airway inflammation
Session:     275 - Antimicrobial treatment and resistance in lower respiratory tract infections
Session Type:     Thematic Poster Session
Date:     Monday, 26 September 2011
Time:     12:50 to 14:40
       
Abs. ID/Title:     4499 (late breaking abstract) - Inhaled calcium salts reduce tobacco smoke induced airway inflammation and improve lung pathology
Session:     460 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Session Type:     Oral Presentation
Date:     Tuesday, 27 September 2011
Time:     presentation is scheduled for 16:30 (14:45 to 16:45 is the time of this session)
About Pulmatrix

Pulmatrix is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases. Pulmatrix's lead proprietary therapies, called inhaled cationic airway lining modulators (iCALM), are a novel approach to prevent and treat acute exacerbations and improve lung function in patients with chronic respiratory diseases. iCALM therapies have broad potential to treat and prevent a wide range of respiratory diseases, including respiratory infections such as influenza; ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive or chronic respiratory diseases such as COPD, asthma, and cystic fibrosis. For additional information about the Company, please visit http://www.pulmatrix.com.

 

Contact: The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com

 

Posted: September 2011

View comments

Hide
(web1)